PDF(Pubmed)
Abstract：
UNASSIGNED: Plantar vein thrombosis (PVT) is a rare condition. Less than 50 cases have been described in the literature. Evidence from interventional and observational studies is sparse or lacking.
UNASSIGNED: To describe a consecutive cohort of patients diagnosed with PVT at a single academic institution over the past 17 years.
UNASSIGNED: We searched medical charts from patients managed at the University Hospital Zurich between 2005 and 2022. PVT was detected through sonography (eg, in the presence of a noncompressible deep vein) and/or magnetic resonance (eg, a vein with a filling defect on non-contrast-enhanced or contrast-enhanced imaging). The study was approved by the local ethics commission.
UNASSIGNED: We identified 45 patients who had been assessed for PVT. After manual check of these cases, we selected 16 patients with a confirmed, objective diagnosis. Median age was 62 (25th-75th percentiles, 46-73) years, and 9 (56%) patients were women. All patients were symptomatic, usually reporting local pain in the foot (100%) and swelling (67%). The most frequent risk factors were cancer (n = 6; 38%) and prior deep vein thrombosis (n = 4; 25%). Overall, 80% of patients received oral anticoagulation and 20% received parenteral anticoagulation for a median of 90 days. Over a median follow-up of 17 months, 2 (12.5%) recurrent venous thromboembolism events were recorded following the discontinuation of anticoagulation. Index vein recanalization occurred in all 15 survivors. One patient died from cancer 2 years after PVT diagnosis.
UNASSIGNED: We provided initial information on the clinical characteristics, treatment, and course of PVT, which partly resembles that of distal deep vein thrombosis.
UNASSIGNED: To describe a consecutive cohort of patients diagnosed with PVT at a single academic institution over the past 17 years.
UNASSIGNED: We searched medical charts from patients managed at the University Hospital Zurich between 2005 and 2022. PVT was detected through sonography (eg, in the presence of a noncompressible deep vein) and/or magnetic resonance (eg, a vein with a filling defect on non-contrast-enhanced or contrast-enhanced imaging). The study was approved by the local ethics commission.
UNASSIGNED: We identified 45 patients who had been assessed for PVT. After manual check of these cases, we selected 16 patients with a confirmed, objective diagnosis. Median age was 62 (25th-75th percentiles, 46-73) years, and 9 (56%) patients were women. All patients were symptomatic, usually reporting local pain in the foot (100%) and swelling (67%). The most frequent risk factors were cancer (n = 6; 38%) and prior deep vein thrombosis (n = 4; 25%). Overall, 80% of patients received oral anticoagulation and 20% received parenteral anticoagulation for a median of 90 days. Over a median follow-up of 17 months, 2 (12.5%) recurrent venous thromboembolism events were recorded following the discontinuation of anticoagulation. Index vein recanalization occurred in all 15 survivors. One patient died from cancer 2 years after PVT diagnosis.
UNASSIGNED: We provided initial information on the clinical characteristics, treatment, and course of PVT, which partly resembles that of distal deep vein thrombosis.
摘要：
■足底静脉血栓形成（PVT）是一种罕见的疾病。文献中描述了不到50例。来自介入和观察性研究的证据很少或缺乏。
■描述过去17年在单一学术机构诊断为PVT的患者的连续队列。
■我们搜索了2005年至2022年间在苏黎世大学医院管理的患者的医疗图表。通过超声检查检测到PVT(例如，在存在不可压缩的深静脉的情况下)和/或磁共振(例如，在非对比增强或对比增强成像中具有充盈缺损的静脉)。这项研究得到了当地伦理委员会的批准。
■我们确定了45例接受过PVT评估的患者。在手动检查这些情况后，我们选取了16例确诊患者,客观诊断。年龄中位数为62岁(第25-75百分位数，46-73）年，9名(56%)患者为女性。所有患者均有症状，通常报告足部局部疼痛（100％）和肿胀（67％）。最常见的危险因素是癌症（n=6;38％）和先前的深静脉血栓形成（n=4;25％）。总的来说,80％的患者接受口服抗凝治疗，20％的患者接受肠胃外抗凝治疗，中位时间为90天。经过17个月的中位随访，2例（12.5％）静脉血栓栓塞事件在停药后记录。所有15名幸存者均发生索引静脉再通。一名患者在PVT诊断2年后死于癌症。
■我们提供了有关临床特征的初步信息，治疗,和PVT课程，部分类似于远端深静脉血栓形成。
■描述过去17年在单一学术机构诊断为PVT的患者的连续队列。
■我们搜索了2005年至2022年间在苏黎世大学医院管理的患者的医疗图表。通过超声检查检测到PVT(例如，在存在不可压缩的深静脉的情况下)和/或磁共振(例如，在非对比增强或对比增强成像中具有充盈缺损的静脉)。这项研究得到了当地伦理委员会的批准。
■我们确定了45例接受过PVT评估的患者。在手动检查这些情况后，我们选取了16例确诊患者,客观诊断。年龄中位数为62岁(第25-75百分位数，46-73）年，9名(56%)患者为女性。所有患者均有症状，通常报告足部局部疼痛（100％）和肿胀（67％）。最常见的危险因素是癌症（n=6;38％）和先前的深静脉血栓形成（n=4;25％）。总的来说,80％的患者接受口服抗凝治疗，20％的患者接受肠胃外抗凝治疗，中位时间为90天。经过17个月的中位随访，2例（12.5％）静脉血栓栓塞事件在停药后记录。所有15名幸存者均发生索引静脉再通。一名患者在PVT诊断2年后死于癌症。
■我们提供了有关临床特征的初步信息，治疗,和PVT课程，部分类似于远端深静脉血栓形成。
